Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Bullboard Posts
Post by Waco4505on Oct 16, 2020 8:59am
121 Views
Post# 31727248

Sona can help

Sona can help

American colleges are becoming hotspots for COVID-19. The New York Times keeps a running survey of more than 1,700 college campuses. The paper has recorded more than 178,000 infections since the start of the pandemic—the vast majority since the new school year began.  

 

What The Times’ infographic doesn’t track, however, is which of those 1,700 colleges have the supplies to fight the virus and which don’t.  

 

Colleges require a huge supply of COVID-19 tests so they can detect who is sick and who isn’t. But not all colleges have equal access to testing. That’s particularly true of America’s Historically Black Colleges and Universities (HBCUs). There’s an enormous testing gap.  

 

This week, Allan Golston, president of the U.S. Program writes about how our foundation is closing that gap. We’re funding a program that will dramatically expand testing capacity at HBCUs.

 

America’s Black community has disproportionally suffered from this virus. In some places, twice as many Black Americans have died of COVID-19 as white Americans, and systemic racism is certainly a major cause. This new funding, we hope, will begin to address some of those inequities, but we know it’s only one small step.

 
Mark Suzman
Chief Executive Officer
Bill & Melinda Gates Foundation

Bullboard Posts